Zacks: Analysts Expect Pulse Biosciences Inc (NASDAQ:PLSE) to Post -$0.61 EPS
Equities analysts expect Pulse Biosciences Inc (NASDAQ:PLSE) to post earnings of ($0.61) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Pulse Biosciences’ earnings. Pulse Biosciences reported earnings per share of ($0.64) in the same quarter last year, which indicates a positive year over year growth rate of 4.7%. The company is expected to announce its next earnings report on Tuesday, October 29th.
According to Zacks, analysts expect that Pulse Biosciences will report full year earnings of ($2.29) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will report earnings of ($1.95) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Pulse Biosciences.
Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04).
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Pulse Biosciences by 17.2% in the 2nd quarter. BlackRock Inc. now owns 734,566 shares of the company’s stock worth $9,695,000 after acquiring an additional 108,059 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Pulse Biosciences by 5.2% in the 2nd quarter. Vanguard Group Inc. now owns 463,194 shares of the company’s stock valued at $6,114,000 after purchasing an additional 22,800 shares during the last quarter. Northern Trust Corp increased its position in shares of Pulse Biosciences by 2.0% in the 2nd quarter. Northern Trust Corp now owns 124,276 shares of the company’s stock valued at $1,640,000 after purchasing an additional 2,454 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Pulse Biosciences by 49.5% in the 4th quarter. Geode Capital Management LLC now owns 117,149 shares of the company’s stock valued at $1,342,000 after purchasing an additional 38,763 shares during the last quarter. Finally, Griffin Asset Management Inc. increased its position in shares of Pulse Biosciences by 11.6% in the 2nd quarter. Griffin Asset Management Inc. now owns 57,315 shares of the company’s stock valued at $757,000 after purchasing an additional 5,955 shares during the last quarter. Hedge funds and other institutional investors own 9.60% of the company’s stock.
Shares of Pulse Biosciences stock traded down $0.08 during mid-day trading on Friday, hitting $11.23. The stock had a trading volume of 110 shares, compared to its average volume of 45,175. The firm has a 50-day moving average of $12.24 and a two-hundred day moving average of $14.40. Pulse Biosciences has a 12-month low of $8.60 and a 12-month high of $19.77. The company has a quick ratio of 12.92, a current ratio of 12.92 and a debt-to-equity ratio of 0.07. The firm has a market cap of $233.25 million, a P/E ratio of -5.10 and a beta of 1.79.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Featured Article: Are all No-Load Funds Equal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.